Everest Medicine’s Nefecon Receives NMPA Approval for the Treatment of Primary IgA Nephropathy
Shots:
- The approval was supported by the results of P-III STUDY (NefIgArd) which showed that Nefecon's treatment impact on kidney function, proteinuria, and microhematuria was higher in the Chinese cohort than it was in the global data set.
- The results of the study depicted that within the Chinese subgroup, the average absolute alteration in eGFR after 24mos. indicated a 66% decrease in the decline of kidney function vs 50% reduction in the loss of eGFR observed in the global dataset
- Nefecon, a patented delayed-release oral formulation of budesonide, a corticosteroid known for its robust glucocorticoid effects and minimal mineralocorticoid activity. Additionally, this Approval results in a $5M milestone payment to Calliditas, to be recorded as Q4 revenue
Ref: PRNewswire | Image: Everest medicines
Related News:- Calliditas Therapeutics Reports the US Regulatory Update on Nefecon for the Treatment of IgA Nephropathy
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
